Pharmaceutical companies AgaMatrix and Sanofi-Aventis have signed a long-term deal to jointly develop and market blood glucose monitoring (BGM) systems.
The agreement will see both firms use AgaMatrix’s WaveSense technology to expand their range of diabetes management techniques.
The new products will be marketed by Sanofi-Aventis through its global diabetes division.
Sanofi spokesman Eric Petreto said: “In building our global diabetes division, our objectives included conducting an exhaustive search for potential partners that have excellent core science, are highly innovative, and have the potential to develop a broad range of products.
“With AgaMatrix, we’ve found a company that can meet all three objectives in the BGM category.”
Sanofi-aventis’ current insulin and device portfolio includes Lantus, the most commonly prescribed type of basal insulin worldwide, Apidra, a leading fast-acting insulin, and its easy-to-use delivery pens SoloSTAR and ClikSTAR.